The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 28, 2014
Filed:
Jul. 05, 2005
Thomas J. Schall, Palo Alto, CA (US);
Zhenhua Miao, San Jose, CA (US);
Robert Berahovich, Berkeley, CA (US);
Zheng Wei, Union City, CA (US);
Maureen Howard, Los Altos, CA (US);
Brett Premack, San Francisco, CA (US);
Thomas J. Schall, Palo Alto, CA (US);
Zhenhua Miao, San Jose, CA (US);
Robert Berahovich, Berkeley, CA (US);
Zheng Wei, Union City, CA (US);
Maureen Howard, Los Altos, CA (US);
Brett Premack, San Francisco, CA (US);
Chemocentryx, Inc., Mt. View, CA (US);
Abstract
The inventors have discovered that a CKβ8-1 truncation variant, CKβ8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CKβ8-1(25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CKβ8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CKβ8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1. This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided. The compositions and methods are useful for vaccine formulations for therapeutic and prophylactic use (immunization) and for production of antibodies.